**1 2 3 4 5 6 7 8 9 10 11 12**

****

**Figure S1.** Western Blot for anti-human aromatase antibody shown in the manuscript as figure (3). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.

**1 2 3 4 5 6 7 8 9 10 11 12**

****

**Figure S2.** Western Blot for anti-human CK7 antibody shown in the manuscript as figure (5). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.



**1 2 3 4 5 6 7 8 9 10 11 12**

**Figure S3.** Western Blot for anti-human EGFR antibody shown in the manuscript as figure (3). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.

**1 2 3 4 5 6 7 8 9 10 11 12**



**Figure S4.** Western Blot for anti-human HAT antibody shown in the manuscript as figure (2). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.



**1 2 3 4 5 6 7 8 9 10 11 12**

**Figure S5.** Western Blot for anti-human LC3 antibody shown in the manuscript as figure (3). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.



**1 2 3 4 5 6 7 8 9 10 11 12**

**Figure S6.** Western Blot for anti-human β-actin antibody shown in the manuscript as figure (3). Lane 1: 0.1% DMSO (control), Lane3: 0.25 µM DOX, Lanes 5 and 6: 1mM EUG and 40 µM AST, respectively, Lanes 7 and 8: 0.25 µM DOX+1mM EUG and 0.25 µM DOX+ 40 µM AST, respectively.